Identifying the Best Follow up Approach for People Who Have Had Treatment to Cure Newly Diagnosed Prostate Cancer

Inclusion criteria:

All hospitals in England that provide radical prostatectomy or radical radiotherapy or focal therapy for prostate cancer and are identified by clinicians as receiving one of the four follow up strategies of interest will be eligible for inclusion in the study.

Individual patients satisfying the following criteria will be eligible for inclusion:

* Having newly-diagnosed non-metastatic, clinically localised prostate cancer (ICD-10 code C61) in the Cancer Registry between 1 January 2018 and 31 December 2023;
* Age 18 or over at diagnosis;
* Completed primary curative treatment at an eligible hospital between 1 January 2019 and 31 December 2023 with either: radical radiotherapy +/- hormones, or radical prostatectomy with curative intent +/- lymphadenectomy, or focal therapy, in keeping with local practice;
* Alive with no disease progression or metastasis 6 months after the date of completion of primary curative treatment.

Exclusion criteria:

* Men who are treated for metastatic cancer; or receiving palliative prostate cancer care;
* Men who have opted out of their data being used as part of national routine data sets will be excluded (https://digital.nhs.uk/services/national-data-opt-out).

Recruitment to the survey component of the study will be limited to a sub-cohort of eligible participants that additionally meet the following criteria:

* Alive;
* Have achieved between three to four and a half years of follow up (from completion of initial curative treatment) during the survey period.